Oncology Handbook
Interactive Reference
Home
Regimens
Color theme
Home
Regimens
Home
Melanoma
Regimens
Melanoma
56 regimens
Subsite
All
Melanoma: Cutaneous — BRAF V600 mutant metastatic melanoma with brain metastases
Melanoma: Cutaneous — BRAF V600 mutant metastatic melanoma, symptomatic brain metastases, untreated
Melanoma: Cutaneous — Melanoma brain metastases
Melanoma: Cutaneous — Oligometastatic melanoma
Melanoma: Cutaneous — Resected stage IV metastatic disease
Melanoma: Cutaneous — Resected stage IV metastatic disease with prior anti-PD-1 exposure
Melanoma: Cutaneous — Stage III
Melanoma: Cutaneous — Stage III resectable
Melanoma: Cutaneous — Stage III/IV resectable
Melanoma: Cutaneous — Stage III/IV resectable with prior anti-PD-1 exposure
Melanoma: Cutaneous — Unresectable stage III or Stage IV metastatic
Melanoma: Cutaneous — Unresectable stage III or Stage IV metastatic with brain metastases
Melanoma: Cutaneous — Unresectable stage III or Stage IV metastatic, BRAF V600 mutant
Melanoma: Cutaneous — Unresectable stage III or Stage IV metastatic, BRAF non-V600 mutations or BRAF gene fusion
Melanoma: Cutaneous — Unresectable stage III or Stage IV metastatic, KIT mutation positive
Melanoma: Cutaneous — Unresectable stage III or Stage IV metastatic, NRAS Q61 mutation positive
Melanoma: Cutaneous — Unresectable stage III or Stage IV metastatic, NTRK1/2/3 gene fusion positive
Melanoma: Cutaneous — Unresectable stage III or Stage IV metastatic, NTRK1/2/3 or ROS1 gene fusion positive
Melanoma: Cutaneous — Unresectable stage III or Stage IV metastatic, ROS1 gene fusion positive
Melanoma: Cutaneous — Unresectable stage III or Stage IV metastatic, previously treated
Melanoma: Cutaneous — Unresectable stage III or Stage IV metastatic, previously treated with anti-PD-1
Metastatic uveal melanoma
Metastatic uveal melanoma, HLA-A*02:01-positive
Metastatic uveal melanoma, hepatic-dominant
Intent
All
Adjuvant
First-line
Second-line+
Metastatic
Other
Line
All
Adjuvant/Neoadjuvant
First-line
Second-line
Any
Search
Reset
Regimen
Setting
Modality
Drugs
Evidence
Category
No regimens match your filters
← Prev
Next →
Regimen Detail
Drugs
Drug
Dose
Route
Schedule
Trial Evidence
Trial
Phase
N
Primary Endpoint
OS
PFS/rPFS
ORR
Key Outcomes
Biomarkers
Marker
Requirement
Mandatory
Required
Optional
Notes